Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia".
Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia".